REFERENCES

1. World Health Organization (WHO) 2002. The World Health Report 2002: Reducing Risks, Promoting Healthy Life.
2. Gupta R, Joshi P, Mohan V. Reddy KS, Yusuf S. Global burden of cardiovascular disease: Epidemiology and causation of coronary heart disease and stroke in India. Heart 2008; 94:16- 26.
3. Gupta S, Gudapati R, Gaurav K, Bhise M. Emerging risk factors for cardiovascular diseases: Indian context. Indian J Endocr Metab 2013; 17: 806-14.
4. Reddy KS, Shah B, Varghese C, Ramadoss A. Responding to the challenge of chronic diseases in India. Lancet 2005; 366: 1744-9.
5. McQueen M.J., Hawken S., Wang X. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the interheart study): a case-control study. Lancet. 2008; 372: 224–233.
6. Gupta R., Guptha S., Agrawal A., Kaul V., Gaur K., Gupta V.P. Secular trends in cholesterol lipoproteins and triglycerides and prevalence of dyslipidemias in an urban Indian population. Lipids Health Dis. 2008; 7: 40.
7. Vidhate D A, Thomas J and Gupte A M. Association of IL-6 with Diabetes Mellitus in Indian Population from Navi Mumbai. International Journal of Recent Trends in Science and Technology 2013, 8: 2: 100-102.
8. Vidhate DA, Thomas J and Gupte A M. IL-6: An important mediator of obesity based inflammation. International Journal of Advanced and Innovative Research 2013; 2: 9: 283-286.
9. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.
10. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001; 357: 1063.
11. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213 –220.
12. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004 Jun 15; 109(23 Suppl 1):III27-32.
13. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84:1086-95.
14. Morel DW, Hessler JR, Chisholm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983; 24: 1070-6.
15. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost. 2006 Mar; 95(3):511-8.
16. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969 Jul; 56(1):111-28.
17. Wilken DEL, Wilken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57:1079. 29.
18. Refsum A, Ueland PM: Homocysteine and cardiovascular disease: Annu Rev Medicine 1998; 49: 31-62.
19. Frosst P, Blom MJ, Milos R, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase: Nat Genet 1995; 10: 111-113.
20. Malinowska A, Chmurzynska A. Polymorphism of genes encoding homocysteine metabolism-related enzymes and risk for cardiovascular disease. Nutr Res 2009; 29: 685-95.
21. Aronow WS, Ahn C: Increased plasma homocysteine is an independent predictor of new coronary events in older persons.Am J Cardiol; 2000, 86: 346-347.
22. Baszczuk A, Kopczynski Z. Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw. 2014; 68:579.
23. Ganguly P and Sreyoshi Fatima Alam. Role of homocysteine in the development of cardiovascular disease. Nutrition Journal 2015; 14: 6: 2-10.
24. Chambers JC, Kooner JS. Homocysteine: an innocent bystander in vascular disease? Eur Heart J 2001; 22:717–9.
25. Deepa, R., Velmurugan, K., Sarvanan, G., Karkuzhah, Diwakanath V. and Mohan, V. (2001). Absence of association between serum homocysteine levels and coronary artery disease in South Indian males. Indian Heart J. 53, 44-47.
26. Yajnik CS, Deshpande SS, Lubree HG, Naik SS, Bhat DS, Uradey BS, et al. Vitamin B12 deficiency and hyperhomocysteinemia in rural and urban Indians. J Assoc Physicians India 2006; 54: 775–82.
27. Wadia RS, Edul NC, Bhagat S, Bandhishi S, Kulkarni R, Sontakke S, et al. Hyperhomocysteinaemia and vitamin B12 deficiency in ischaemic strokes in India. Ann Indian Acad Neurol 2004; 7: 387–92.
28. Zhang S, Yong-Yi B, Luo LM, Xiao WK, Wu HM, Ye P. Association between serum homocysteine and arterial stiffness in elderly: a community-based study. J Geriatr Cardiol. 2014; 11:32–8.
29. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-81.
30. Tanriverdi H, Evrengul H. Effect of homocysteine-induced oxidative stress on endothelial function in coronary slow-flow. Cardiology 2007; 107: 313 – 320.
31. Yeolkar M.E., Shete M.M. Homocysteine and hypertension. J. Assoc. Physicians India. 2002; 50:29–35.
32. Ali MK, Narayan KM, Tandon N. Diabetes and coronary heart disease: Current perspectives. Indian J Med Res 2010; 132:587-97.